Showing posts with label diagnosis. Show all posts
Showing posts with label diagnosis. Show all posts

Thursday, September 26, 2013

0 Recent advances in diagnosis and therapy of allergic rhinitis and asthma in childhood




Recent advances in diagnosis and therapy of allergic rhinitis and asthma in childhood



E. Calamelli, G. Ricci, A. Pession



Abstract



Some of the most recent advances in the diagnosis and treatment of childhood asthma and allergies are here reviewed. New perspectives have been opened by in vitro diagnostic tests for allergies based on a molecular approach and novel approaches to in vivo tests (SPT or FEno). A better characterization of the patients is opening new classifications of allergic asthma and rhinitis phenotypes, which allow personalizing management disease programs and targeting pharmacotherapy. Educational programs and better communication are improving awareness and compliance with medical prescriptions and adherence to guidelines. Increasing information is being acquired on the mechanisms, efficacy and safety profiles of anti-asthma and anti-allergic drugs, including antihistamines, inhaled corticosteroids, long acting beta agonists, antibiotics, anti-IgE antibodies. Progress in biotechnologies is fostering new approaches to allergen-specific immunotherapy (subcutaneous, sublingual) concerning the quality, mechanisms, efficacy and safety of allergen products.



Keywords



Allergen-specific immunotherapy, allergic rhinitis, asthma, children, inhaled corticosteroids, IgE, longacting beta-2 agonists, nitric oxide, omalizumab, skin prick test.


Full Text: PDF 






Wednesday, September 25, 2013

Don’t assume ICD-10 diagnosis codes -- 424.1 will split under the new cardiology codes next year

 The coming year there will be major code changes when ICD-10 comes into effect. Like any other practice there will be major changes for cardiology codes. For instance, there will be new code set divides for diagnosis code 424.1 under ICD 9-CM that is used to report aortic valve disorders, and you need to ensure that you are updated with all the code changes to keep your practice compliant and profitable. A disorder of the aortic valve refers to a problem with the valve between the aorta and the left ventricle.


When ICD-10 becomes effective then there will be a range of codes specifying 424.1 that will be from 135.0 – 135.9. There will be a range of codes to choose from for multiple aortic valve disorder codes in the I35. – range under ICD-10. ICD-10 will have separate codes for stenosis, insufficiency, stenosis with insufficiency, other, and unspecified.


To ensure correct coding you need to ensure that you document correctly if the aortic valve disease is rheumatic or not. You also need to ensure that you have adequate knowledge regarding whether the condition is congenital because it will affect the choice of codes that will be used. Since there will be multiple code options for aortic valve disorders under ICD-10, documentation needs to be specific about the type of disorder to identify the most specific code.


There are some tips that can be followed to code correctly. If the documentation shows stenosis and insufficiency then only the code 135.2 should be used instead of I35.0 and I35.1 together. Insufficiency can also be documented by using incompetence or regurgitation. When 135.8 is used the term “other” specifies that the physician documented the type, but ICD-10 will not have any code that will specify the documented type. The “unspecified” in I35.9 would mean that the physician did not document the type.


Tuesday, September 24, 2013

0 Diagnosis and Management of Asthma (ICSI Guideline)


Asthma, Diagnosis and Management of (Guideline)


Released 07/2012





ICSI has made a significant format enhancement in our scientific documents. All scientific documents (excluding Order Sets) now have “interactive” capability that allows a user to click on various links in the document and easily navigate from one area to another. For example, you can click on an algorithm box (those denoted with blue text and those that refer to other algorithm boxes) and link directly to the supporting annotation.


A tip for quickly going back and forth within the document:
Go to View, Toolbars, More Tools, Page Navigation, Previous View.
This should give you a back arrow tool that will allow you to go back and forth between views easily.


Note: The interactive links within ICSI PDF guidelines may not work on some mobile devices. However, the GoodReader App (and possibly some other “reader” applications) will allow anyone to open ICSI interactive PDF Guidelines on their mobile device and utilize most of the interactive capabilities. Scope and Target Population:
This guideline addresses the diagnosis, emergent, inpatient and outpatient management of acute and chronic asthma in all patients over five years of age who present with asthma-like symptoms or have been diagnosed with asthma.


Aims:



  1. Increase the rate of patients five years and older who have accurate assessment of asthma severity and control through the use of objective measures of lung function and symptoms.

  2. Increase the rate of patients five years and older who have written asthma action plans and timely and accurate assessment of asthma exacerbation.

  3. Increase the rate of patients five years and older who have appropriate treatment and management of asthma in inpatient care settings.

  4. Increase the rate of patients five years and older who have follow-up visits to ensure asthma control is maintained and appropriate therapy is administered following any visit for asthma or medication adjustment.


Clinical Highlights:



  • Conduct interval evaluations of asthma including medical history and physical examination, assessment of asthma triggers and allergens, measurement of pulmonary function, and consideration of consultation and/or allergy testing.

  • Assess control using objective measures and a validated asthma control tool.

  • Match therapy with asthma control.

  • Provide asthma education to patients and parents of pediatric patients. Education should include basic facts about asthma, how medications work, inhaler technique, a written action plan including home peak flow rate monitoring or a symptom diary, environmental control measures, and emphasis on the need for regular follow-up visits.


Additional Background:
This guideline closely follows the recommendations of the: National Asthma Education Program Expert Panel Report 2, Guidelines for the Diagnosis and Management of Asthma. NIH Publication No. 97-4051. U.S. Department of Health and Human Services, Public Health Service/National Institutes of Health/National Heart, Lung and Blood Institute.




Saturday, September 21, 2013

0 Ambulatory models of care for obstructive sleep apnoea: Diagnosis and management





You have free access to this content

Ambulatory models of care for obstructive sleep apnoea: Diagnosis and management





  1. Ching Li Chai-Coetzer1,2,*, 

  2. Nick A. Antic1,2, 

  3. R. Doug McEvoy1,2


Article first published online: 25 APR 2013

DOI: 10.1111/resp.12071






Respirology



Respirology



Volume 18, Issue 4, pages 605–615, May 2013









Keywords:




  • ambulatory care;

  • continuous positive airway pressure;

  • cost-effectiveness;

  • obstructive sleep apnoea;

  • polysomnography





Abstract



The high prevalence of obstructive sleep apnoea (OSA) and increasing awareness of its potential health consequences has placed significant pressure on laboratory-based sleep services leading to growing waiting lists and delays in diagnosis and treatment. Consequently, there has been increasing interest in the use of simplified, ambulatory models of care involving clinical prediction tools, portable sleep monitoring and home autotitrating continuous positive airway pressure. Researchers are also exploring the potential role for a wider range of health-care providers, including trained nurses and general practitioners, in the primary management of OSA. Recent randomized, controlled studies evaluating the clinical effectiveness of ambulatory management strategies versus traditional laboratory-based care for patients with OSA have consistently demonstrated that comparable patient outcomes can be achieved. The cost-effectiveness of these strategies is currently being debated, and further research examining the long-term economic implications of ambulatory models of care is needed.






Monday, September 16, 2013

0 Acute rhinosinusitis: New guidelines for diagnosis and treatment


Journal of the American Academy of Physician Assistants:


doi: 10.1097/01.JAA.0000431519.28443.5e

Special Topics in Otolaryngology






Acute rhinosinusitis: New guidelines for diagnosis and treatment



Teeters, Jennifer ATC; Boles, Michelle; Ethier, Julie; Jenkins, Ambria; Curtis, L. Gail PA-C, MPAS




Free Access





Article Outline


Collapse Box

Author Information





Jennifer Teeters, Michelle Boles, Julie Ethier, and Ambria Jenkins are graduates of the PA program at Wake Forest School of Medicine, Winston-Salem, North Carolina. L. Gail Curtis is an associate professor and vice chair of the department of physician assistant studies at Wake Forest School of Medicine. The authors have indicated no relationships to disclose relating to the content of this article.

Roy A. Borchardt, PA-C, PhD, department editor.




Collapse Box

Abstract





ABSTRACT: New treatment guidelines for acute rhinosinusitis outline when antibiotic therapy is appropriate, as well as describe evidence-based treatment to relieve symptoms, prevent complications, and prevent chronic disease.


Article Tools





0 Schnitzler"s syndrome: diagnosis, treatment, and follow-up


You have free access to this content

Schnitzler’s syndrome: diagnosis, treatment, and follow-up


Abstract



Schnitzler’s syndrome is characterized by recurrent urticarial rash and monoclonal gammopathy, associated with clinical and biological signs of inflammation and a long-term risk of AA amyloidosis and overt lymphoproliferation. An extensive literature review was performed, and the following questions were addressed during an expert meeting: In whom should Schnitzler’s syndrome be suspected? How should the diagnosis of Schnitzler’s syndrome be established? How should a patient with Schnitzler’s syndrome be treated? How should a patient with Schnitzler’s syndrome be followed up?. A diagnosis of Schnitzler’s syndrome is considered definite in any patient with two obligate criteria: a recurrent urticarial rash and a monoclonal IgM gammopathy, and two of the following minor criteria: recurrent fever, objective signs of abnormal bone remodeling, elevated CRP level or leukocytosis, and a neutrophilic infiltrate on skin biopsy. It is considered probable, if only 1 minor criterion is present. In patients with monoclonal IgG gammopathies, diagnosis is definite if three minor criteria are present and possible if two are present. First-line treatment in patients with significant alteration of quality of life or persistent elevation of markers of inflammation should be anakinra. Follow-up should include clinical evaluation, CBC and CRP every 3 months and MGUS as usually recommended.










  1. A. Simon1, 

  2. B. Asli2, 

  3. M. Braun-Falco3, 

  4. H. De Koning4, 

  5. J.-P. Fermand2, 

  6. C. Grattan5,

  7. K. Krause6, 

  8. H. Lachmann7, 

  9. C. Lenormand8, 

  10. V. Martinez-Taboada9, 

  11. M. Maurer6, 

  12. M. Peters10, 

  13. R. Rizzi11, 

  14. F. Rongioletti12, 

  15. T. Ruzicka3, 

  16. L. Schnitzler13, 

  17. B. Schubert14,

  18. J. Sibilia15, 

  19. D. Lipsker8


Article first published online: 9 MAR 2013

DOI: 10.1111/all.12129






Sunday, September 15, 2013

0 Acute rhinosinusitis: New guidelines for diagnosis and treatment




Journal of the American Academy of Physician Assistants:


doi: 10.1097/01.JAA.0000431519.28443.5e

Special Topics in Otolaryngology






Acute rhinosinusitis: New guidelines for diagnosis and treatment



Teeters, Jennifer ATC; Boles, Michelle; Ethier, Julie; Jenkins, Ambria; Curtis, L. Gail PA-C, MPAS




Free Access





Article Outline


Collapse Box

Author Information





Jennifer Teeters, Michelle Boles, Julie Ethier, and Ambria Jenkins are graduates of the PA program at Wake Forest School of Medicine, Winston-Salem, North Carolina. L. Gail Curtis is an associate professor and vice chair of the department of physician assistant studies at Wake Forest School of Medicine. The authors have indicated no relationships to disclose relating to the content of this article.

Roy A. Borchardt, PA-C, PhD, department editor.




Collapse Box

Abstract





ABSTRACT: New treatment guidelines for acute rhinosinusitis outline when antibiotic therapy is appropriate, as well as describe evidence-based treatment to relieve symptoms, prevent complications, and prevent chronic disease.


Article Tools










Open Access


Research


The role of uPAR in epithelial-mesenchymal transition in small airway epithelium of patients with chronic obstructive pulmonary disease



Qin Wang, Yunshan Wang, Yi Zhang, Yuke Zhang and Wei Xiao










For all author emails, please log on.








Respiratory Research 2013, 14:67 doi:10.1186/1465-9921-14-67

Published: 28 June 2013





Abstract (provisional)


Background


Epithelial-mesenchymal transition (EMT) plays a crucial role in small airway fibrosis of patients with chronic obstructive pulmonary disease (COPD). Increasing evidence suggests that the urokinase plasminogen activator receptor (uPAR) is involved in the pathogenesis of COPD. Increased uPAR expression has been implicated in the promotion of EMT in numerous cancers; however the role of uPAR in EMT in small airway epithelial cells of patients with COPD remains unclear. In this study, we investigated the degree of EMT and uPAR expression in lung epithelium of COPD patients, and verified the effect of uPAR on cigarette smoke extract (CSE)-induced EMT in vitro.

Methods


The expression of EMT biomarkers and uPAR was assessed in lung epithelium specimens from non-smokers (n = 25), smokers (n = 25) and non-smokers with COPD (n = 10) and smokers with COPD (n = 18). The role of uPAR on CSE-induced EMT in human small airway epithelial cells (HSAEpiCs) was assessed by silencing uPAR expression in vitro.

Results


Markers of active EMT and uPAR expression were significantly increased in the small airway epithelium of patients with COPD compared with controls. We also observed a significant correlation between uPAR and vimentin expression in the small airway epithelium. In vitro, CSE-induced EMT in HSAEpiCs was associated with high expression of uPAR, and targeted silencing of uPAR using shRNA inhibited CSE-induced EMT. Finally, we demonstrate that the PI3K/Akt signaling pathway is required for uPAR-mediated EMT in HSAEpiCs.

Conclusions


A uPAR-dependent signaling pathway is required for CSE-induced EMT, which contributes to small airway fibrosis in COPD. We propose that increased uPAR expression in the small airway epithelium of patients with COPD participates in an active EMT process.






The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.










The association between COPD and heart failure risk: a review




Article has an altmetric score of 1




Review


(213) Total Article Views





Authors: de Miguel Díez J, Chancafe Morgan J, Jiménez García R


Published Date June 2013 Volume 2013:8 Pages 305 – 312
DOI: http://dx.doi.org/10.2147/COPD.S31236
















Javier de Miguel Díez,1 Jorge Chancafe Morgan,1 Rodrigo Jiménez García2


1Pulmonology Department, Gregorio Maranon University Hospital, Complutense University of Madrid, Madrid, Spain; 2Preventive Medicine and Public Health Teaching and Research Unit, Department of Health Sciences, Rey Juan Carlos University, Madrid, Spain


Abstract: Chronic obstructive pulmonary disease (COPD) is commonly associated with heart failure (HF) in clinical practice since they share the same pathogenic mechanism. Both conditions incur significant morbidity and mortality. Therefore, the prognosis of COPD and HF combined is poorer than for either disease alone. Nevertheless, usually only one of them is diagnosed. An active search for each condition using clinical examination and additional tests including plasma natriuretic peptides, lung function testing, and echocardiography should be obtained. The combination of COPD and HF presents many therapeutic challenges. The beneficial effects of selective ß1-blockers should not be denied in stable patients who have HF and coexisting COPD. Additionally, statins, angiotensin-converting enzyme inhibitors, and angiotensin-receptor blockers may reduce the morbidity and mortality of COPD patients. Moreover, caution is advised with use of inhaled ß2-agonists for the treatment of COPD in patients with HF. Finally, noninvasive ventilation, added to conventional therapy, improves the outcome of patients with acute respiratory failure due to hypercapnic exacerbation of COPD or HF in situations of acute pulmonary edema. The establishment of a combined and integrated approach to managing these comorbidities would seem an appropriate strategy. Additional studies providing new data on the pathogenesis and management of patients with COPD and HF are needed, with the purpose of trying to improve quality of life as well as survival of these patients.


Keywords: chronic obstructive pulmonary disease, heart failure



Post to:
CannoteaCiteulikeDel.icio.usFacebookLinkedInTwitter










Logo of bmjo









BMJ Open. 2013; 3(6): e003177.

Published online 2013 June 19. doi:  10.1136/bmjopen-2013-003177




PMCID: PMC3693416





The effects of a multisite aerobic exercise intervention on asthma morbidity in sedentary adults with asthma: the Ex-asthma study randomised controlled trial protocol








Abstract




Objective


Aerobic exercise can improve cardiovascular fitness and does not seem to be detrimental to patients with asthma, though its role in changing asthma control and inflammatory profiles is unclear. The main hypothesis of the current randomised controlled trial is that aerobic exercise will be superior to usual care in improving asthma control. Key secondary outcomes are asthma quality of life and inflammatory profiles.



Design


A total of 104 sedentary adults with physician-diagnosed asthma will be recruited. Eligible participants will undergo a series of baseline assessments including: the asthma control questionnaire; the asthma quality-of-life questionnaire and the inflammatory profile (assessed from both the blood and sputum samples). On completion of the assessments, participants will be randomised (1:1 allocation) to either 12-weeks of usual care or usual care plus aerobic exercise. Aerobic exercise will consist of three supervised training sessions per week. Each session will consist of taking a short-acting bronchodilator, 10 min of warm-up, 40 min of aerobic exercise (50–75% of heart rate reserve for weeks 1–4, then 70–85% for weeks 5–12) and a 10 min cool-down. Within 1 week of completion, participants will be reassessed (same battery as at baseline). Analyses will assess the difference between the two intervention arms on postintervention levels of asthma control, quality of life and inflammation, adjusting for age, baseline inhaled corticosteroid prescription, body weight change and pretreatment dependent variable level. Missing data will be handled using standard multiple imputation techniques.



Ethics and dissemination


The study has been approved by all relevant research ethics boards. Written consent will be obtained from all participants who will be able to withdraw at any time.



Results


The result will be disseminated to three groups of stakeholder groups: (1) the scientific and professional community; (2) the research participants and (3) the general public.



Registration Details ClinicalTrials.gov Identifier


NCT00953342



Keywords: Exercise, Quality of life, Inflammation





Formats:














Open Access


Research


Nocturnal CPAP improves walking capacity in COPD patients with obstructive sleep apnoea



Tsai-Yu Wang1†, Yu-Lun Lo1†, Kang-Yun Lee1, Wen-Te Liu2,3, Shu-Min Lin1, Ting-Yu Lin1,Yung-Lun Ni4, Chao-Yung Wang5, Shu-Chuan Ho1,3 and Han-Pin Kuo1*








1Department of Thoracic Medicine, Chang Gung Memorial Hospital and Chang Gung University, School of Medicine, Taipei, Taiwan

2Division of Pulmonary, Department of Internal Medicine, Shuang Ho Hospital, Taipei, Taiwan

3School of Respiratory Therapy, College of Medicine, Taipei Medical University, Taipei, Taiwan

4Department of Chest Medicine, Buddhist Tzu Chi General Hospital, Taichung Branch, Taichung, Taiwan

5Department of Cardiology Medicine, Chang Gung Memorial Hospital and Chang Gung University, School of Medicine, Taipei, Taiwan


For all author emails, please log on.








Respiratory Research 2013, 14:66 doi:10.1186/1465-9921-14-66



The electronic version of this article is the complete one and can be found online at:http://respiratory-research.com/content/14/1/66

















Received:11 February 2013
Accepted:17 June 2013
Published:19 June 2013


© 2013 Wang et al.; licensee BioMed Central Ltd. 

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.







Abstract



Background


Exercise limitation is an important issue in patients with chronic obstructive pulmonary disease (COPD), and it often co-exists with obstructive sleep apnoea (overlap syndrome). This study examined the effects of nocturnal continuous positive airway pressure (CPAP) treatment on walking capacity in COPD patients with or without obstructive sleep apnoea.

Methods


Forty-four stable moderate-to-severe COPD patients were recruited and completed this study. They all underwent polysomnography, CPAP titration, accommodation, and treatment with adequate pressure. The incremental shuttle walking test was used to measure walking capacity at baseline and after two nights of CPAP treatment. Urinary catecholamine and heart rate variability were measured before and after CPAP treatment.

Results


After two nights of CPAP treatment, the apnoea-hypopnoea index and oxygen desaturation index significantly improved in both overlap syndrome and COPD patients, however these changes were significantly greater in the overlap syndrome than in the COPD group. Sleep architecture and autonomic dysfunction significantly improved in the overlap syndrome group but not in the COPD group. CPAP treatment was associated with an increased walking capacity from baseline from 226.4 ± 95.3 m to 288.6 ± 94.6 m (P < 0.05), and decreased urinary catecholamine levels, pre-exercise heart rate, oxygenation, and Borg scale in the overlap syndrome group. An improvement in the apnoea-hypopnoea index was an independent factor associated with the increase in walking distance (r = 0.564).

Conclusion


Nocturnal CPAP may improve walking capacity in COPD patients with overlap syndrome.

Viewing options


Trial registration





Keywords: 

Chronic obstructive pulmonary disease; Obstructive sleep apnoea; Walking capacity; Autonomic dysfunction; Continuous positive airway pressure










Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis




Article has an altmetric score of 1




Original Research


(419) Total Article Views





Authors: Yawn BP, Li YF, Tian HJ, Zhang J, Arcona S, Kahler KH


Published Date June 2013 Volume 2013:8 Pages 295 – 304
DOI: http://dx.doi.org/10.2147/COPD.S42366
















Barbara P Yawn,1 Yunfeng Li,2 Haijun Tian,2 Jie Zhang,2 Steve Arcona,2 Kristijan H Kahler2


1Department of Research, Olmsted Medical Center, Rochester, MN, USA; 2Department of Health Economics and Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA


Background: The use of inhaled corticosteroids in patients with chronic obstructive pulmonary disease (COPD) has been associated with an increased risk of pneumonia in controlled clinical trials and case-control analyses.
Objective: Using claims databases as a research model of real-world diagnosis and treatment, to determine if the use and dose of inhaled corticosteroids (ICS) among patients with newly diagnosed COPD are associated with increased risk of pneumonia.
Patients and methods: This was a retrospective cohort analysis of patients diagnosed with COPD between January 01, 2006 and September 30, 2010, drawn from databases (years 2006–2010). Patients (aged ≥45 years) were followed until first pneumonia diagnosis, end of benefit enrollment, or December 31, 2010, whichever was earliest. A Cox proportional hazard model was used to assess the association of ICS use and risk of pneumonia, controlling for baseline characteristics. Daily ICS use was classified into low, medium, and high doses (1 µg–499 µg, 500 µg–999 µg, and ≥1000 µg fluticasone equivalents daily) and was modeled as a time-dependent variable.
Results: Among 135,445 qualifying patients with a total of 243,097 person-years, there were 1020 pneumonia incidences out of 5677 person-years on ICS (crude incidence rate, 0.180 per person-year), and 27,730 pneumonia incidences out of 237,420 person-years not on ICS (crude incidence rate, 0.117 per person-year). ICS use was associated with a dose-related increase in risk of pneumonia, with adjusted hazard ratios (versus no use; (95% confidence interval) of 1.38 (1.27–1.49) for low-dose users, 1.69 (1.52–1.88) for medium-dose users, and 2.57 (1.98–3.33) for high-dose users (P - 0.01 versus no use and between doses).
Conclusion: The use of ICS in newly diagnosed patients with COPD is potentially associated with a dose-related increase in the risk of pneumonia.


Keywords: COPD, ICS, LABA, pneumonia



Post to:
CannoteaCiteulikeDel.icio.usFacebookLinkedInTwitter













Thorax 68:658-663 doi:10.1136/thoraxjnl-2012-203109




  • Epidemiology



  • Original article



Effectiveness of influenza vaccination in working-age adults with diabetes: a population-based cohort study


Open Access









  1. Jeffrey A Johnson1


+Author Affiliations




  1. 1Department of Public Health Sciences, University of Alberta, Edmonton, Canada




  2. 2Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada




  3. 3Department of Community Health Sciences, University of Manitoba, Winnipeg, Canada





  1. Correspondence toDr Jeffrey A Johnson, 2-040G Li Ka Shing Center for Health Research Innovation, 8602 112 Street, Department of Public Health Sciences, University of Alberta, Edmonton, Canada, AB T6G 2E1; jeff.johnson@ualberta.ca




  • Received 7 December 2012


  • Revised 7 February 2013


  • Accepted 2 March 2013


  • Published Online First 27 March 2013




Abstract




Background Guidelines recommend influenza vaccinations in all diabetic adults, but there is limited evidence to support vaccinating working-age adults ( – 65 years) with diabetes. We examined the effectiveness of influenza vaccine in this subgroup, compared with elderly adults (+ 65 years) for whom vaccination recommendations are well accepted.








Methods We identified all adults with diabetes, along with a sample of age-matched and sex-matched comparison subjects without diabetes, from 2000 to 2008, using administrative data from Manitoba, Canada. With multivariable Poisson regression, we estimated vaccine effectiveness (VE) on influenza-like illnesses (ILIs), pneumonia and influenza (PI) hospitalisations and all-cause (ALL) hospitalisations during periods of known circulating influenza. Analyses were replicated outside of influenza season to rule out residual confounding.



Results We included 543 367 person-years of follow-up, during which 223 920 ILI, 5422 PI and 94 988 ALL occurred. The majority (58%) of adults with diabetes were working age. In this group, influenza vaccination was associated with relative reductions in PI (43%, 95% CI 28% to 54%) and ALL (28%, 95% CI 24% to 32%) but not ILI (−1%, 95% CI −3% to 1%). VE was similar in elderly adults for ALL (33–34%) and PI (45–55%), although not ILI (12–13%). However, similar estimates of effectiveness were also observed for all three groups during non-influenza control periods.



Conclusions Working-age adults with diabetes experience similar benefits from vaccination as elderly adults, supporting current diabetes-specific recommendations. However, these benefits were also manifest outside of influenza season, suggesting residual bias. Vaccination recommendations in all high-risk adults would benefit from randomised trial evidence.




This Article







  1. Supplementary Data


  2. All Versions of this Article:

    1. thoraxjnl-2012-203109v1


    2. 68/7/658 most recent






This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/3.0/ andhttp://creativecommons.org/licenses/by-nc/3.0/legalcode